Amgen (AMGN) - Get Report , along with Regeneron (REGN) - Get Report announced Tuesday they have inked separate deals to expand their anti-cancer research programs. According to TheStreet's Adam Feuerstein, the new deals indicate a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth. Amgen is set to pay $65 million to license rights to a technology from Advaxis in order to develop immunotherapy treatments to help combat brain tumors. Meanwhile, the Regeneron partnership was signed with privately held Adicet Bio and aims to target blood cancers and solid tumors through a form of therapy similar to the those being developed by Juno Therapeutics and Kite Pharma.
Employees of TheStreet are restricted from owning individual securities.